Full Press Release Details
ANAVEX ANNOUNCES RESULTS OF ANNUAL MEETING
Athens, Greece, May 4, 2010 Anavex Life Sciences Corp.
( ANAVEX or the Company ) (OTCBB: AVXL) announced that it held its annual
meeting of stockholders on April 28, 2010 at which its stockholders re-elected
Harvey Lalach, Alison Ayers, Cameron Durrant and David Tousley as the directors
of the Company. The board of directors of the Company did not nominate Dr. Herve
de Kergrohen as a candidate for a director at the annual meeting and, as a
result, he ceased being a director of the Company following the annual meeting.
At the annual meeting, its stockholders also ratified the appointment of BDO
Dunwoody LLP as its independent registered public accounting firm
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is an emerging
biopharmaceutical company engaged in the discovery and development of novel drug
targets for the treatment of cancer and neurological diseases such as
Alzheimer's, epilepsy and depression. The company's proprietary SIGMACEPTOR
Discovery Platform involves the rational design of drug compounds that fulfill
specific criteria based on unmet market needs and new scientific advances.
Selected drug candidates demonstrate high, non-exclusive affinity for sigma
receptors, which are involved in the modulation of multiple cellular biochemical
ANAVEX's SIGMACEPTOR -N program involves the development of
novel and original drug candidates that target neurological and
neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain).
The company's lead drug candidates exhibit high, non-exclusive affinity for
sigma receptors with strong evidence for anti-amnesic and neuroprotective
properties. The company believes that oxidative stress, not amyloid-beta, is the
cause of Alzheimer's. ANAVEX 1-41 and ANAVEX 2-73 modulate sigma receptors, a
unique class of receptor molecules, to guard against oxidative stress and repair
cells compromised by its effects. So far, through the advanced pre-clinical
phase of development, the compounds have performed extremely well in
well-recognized animal models of Alzheimer's disease, underscoring the promise
of the company s new alternative approach to the disease.
ANAVEX s SIGMACEPTOR -C program involves the development of
novel and original drug candidates targeting cancer. The company's lead drug
candidates exhibit high, non-exclusive affinity for sigma receptors with strong
evidence for selective pro-apoptotic, anti-metastatic and low toxicity
properties in various types of solid cancers. ANAVEX 7-1037 has already
demonstrated its ability to significantly delay the growth of cancerous tumors
in patient-derived xenografts during advanced pre-clinical studies.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development
Email: info@anavex.com
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092
Email: ir@anavex.com